Vertical-velocity skewness in the marine stratus-topped boundary layer

Vertical-velocity skewness, S(sub w), in a turbulent flow is important in several regards. S(sub w) is indicative of the structure of the motion when it is positive, updrafts are narrower and stronger than surrounding downdrafts, and vice versa. Aircraft measurements often suggest cool, narrow downdrafts at some distance below the stratus cloud top, indicating a negative S(sub w) (Nicholls and Leighton, 1986). This seems natural as the turbulence within the stratus-topped boundary layer (CTBL) is driven mainly by the radiative cooling at the cloud top (although sometimes surface heating can also play a major role). One expects intuitively (e.g., Nicolls, 1984) that, in the situations where cloud-top cooling and surface heating coexist, the turbulence statistics in the upper part of the CTBL are influenced more by the cloud-top cooling, while those in the lower part, more by the surface heating. Thus one expects negative S(sub w) in the upper part, and positive in the lower part, in this case. In contradistinction, large-eddy simulations (LES) of the CTBL show just the opposite: the S(sub w) is positive in the upper part and negative in the lower part of the layer. To understand the nature of vertical-velocity skewness, the simplest type of buoyancy-driven turbulence (turbulent Rayleigh-Benard convection) is studied through direct numerical simulation

Passive dynamic controllers for nonlinear mechanical systems

A methodology for model-independant controller design for controlling large angular motion of multi-body dynamic systems is outlined. The controlled system may consist of rigid and flexible components that undergo large rigid body motion and small elastic deformations. Control forces/torques are applied to drive the system and at the same time suppress the vibration due to flexibility of the components. The proposed controller consists of passive second-order systems which may be designed with little knowledge of the system parameter, even if the controlled system is nonlinear. Under rather general assumptions, the passive design assures that the closed loop system has guaranteed stability properties. Unlike positive real controller design, stabilization can be accomplished without direct velocity feedback. In addition, the second-order passive design allows dynamic feedback controllers with considerable freedom to tune for desired system response, and to avoid actuator saturation. After developing the basic mathematical formulation of the design methodology, simulation results are presented to illustrate the proposed approach to a flexible six-degree-of-freedom manipulator

HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study.

BACKGROUND AND OBJECTIVES: There is a need for local anesthetics that provide consistent analgesia through 72 hours after surgery. This study evaluates the use of HTX-011 (bupivacaine and meloxicam in Biochronomerpolymer technology), an extended-release, dual-acting local anesthetic, in reducing both postoperative pain over 72 hours and postoperative opioid use when compared with bupivacaine hydrochloride (HCl) and saline placebo. Inclusion of low-dose meloxicam in HTX-011 is designed to reduce local inflammation caused by surgery, potentiating the analgesic effect of bupivacaine. Previously, significant synergy has been observed with bupivacaine and meloxicam with both given locally together. METHODS: EPOCH 1 was a randomized, double-blind, placebo-controlled and active-controlled phase III study in subjects undergoing a primary unilateral, distal, first metatarsal bunionectomy in which subjects received either a single intraoperative dose of HTX-011, immediate-release bupivacaine HCl or saline placebo. RESULTS: A total of 412 subjects were dosed. The results for the primary and all four key secondary endpoints were statistically significant in favor of HTX-011. HTX-011 demonstrated superior, sustained pain reduction through 72 hours, significantly reduced opioid consumption and resulted in significantly more opioid-free subjects compared with saline placebo and bupivacaine HCl. Safety was similar across groups with fewer opioid-related adverse events observed in the HTX-011 group. CONCLUSIONS: HTX-011 demonstrated significant reduction in postoperative pain through 72 hours with significant reduction in opioid consumption and a significant increase in the proportion of opioid-free subjects compared with saline placebo and the most widely used local anesthetic, bupivacaine HCl. TRIAL REGISTRATION NUMBER: NCT03295721